COMP <GO>
RRX vs TMO // OPERATING MARGIN
Regal Rexnord Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RRX 4
— TMO 9
▲ OPERATING MARGIN LEADER: TMO
LAST: $157.24 (-3.90%) • MKT CAP: $10.90B
operating-margins
11.50%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
operating-margins
17.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RRX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RRX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 37.40% | 41.00% | -3.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.90% | 9.30% | -4.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.8x | 30.4x | -10.60 | RRX | /valuation <GO> |
| Free Cash Flow Yield | 8.20% | 2.40% | +5.80 | RRX | /fcf-yield <GO> |
| Operating Margin ACTIVE | 11.50% | 17.40% | -5.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.70% | 15.10% | -10.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.10% | 3.90% | -2.80 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.85% | 0.24% | +0.61 | RRX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.92 | 4.50 | -2.58 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 59.1 | -10.05 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.94 | +0.04 | RRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.3x | 36.3x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.90B | $262.22B | -$251.32B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RRX REV | TMO REV | RRX GROSS % | TMO GROSS % | RRX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.93B | $44.56B | 37.4% | 44.0% | $893.1M | $6.29B |
| FY 2024 | $6.03B | $42.88B | 36.3% | 44.0% | $499.9M | $7.27B |
| FY 2023 | $6.25B | $42.86B | 44.0% | 44.0% | $434.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RRX // BETA 0.98
TMO // BETA 0.94